New Mexico Educational Retirement Board trimmed its holdings in Catalent, Inc. (NYSE:CTLT – Free Report) by 3.5% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 8,300 shares of the company’s stock after selling 300 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Catalent were worth $545,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. FNY Investment Advisers LLC purchased a new position in Catalent in the 1st quarter worth approximately $34,000. Covestor Ltd lifted its holdings in Catalent by 84.9% in the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock worth $62,000 after purchasing an additional 258 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Catalent in the 1st quarter worth approximately $48,000. Compagnie Lombard Odier SCmA purchased a new position in Catalent in the 4th quarter worth approximately $34,000. Finally, Allworth Financial LP lifted its holdings in Catalent by 107.3% in the 1st quarter. Allworth Financial LP now owns 852 shares of the company’s stock worth $56,000 after purchasing an additional 441 shares in the last quarter.
Catalent Stock Performance
CTLT stock opened at $46.51 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91. The business’s fifty day simple moving average is $43.08 and its two-hundred day simple moving average is $52.22. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $115.08. The firm has a market cap of $8.38 billion, a price-to-earnings ratio of 211.42, a PEG ratio of 5.59 and a beta of 1.21.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on CTLT shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Catalent from $29.00 to $37.00 in a research note on Monday, May 22nd. Morgan Stanley reduced their price objective on Catalent from $85.00 to $50.00 in a research note on Monday, May 22nd. Bank of America lifted their price objective on Catalent from $28.00 to $33.00 in a research note on Tuesday, June 13th. JPMorgan Chase & Co. downgraded Catalent from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $90.00 to $45.00 in a research note on Sunday, May 21st. Finally, Robert W. Baird boosted their target price on Catalent from $35.00 to $47.00 in a research report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $56.25.
Catalent Profile
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More
- Five stocks we like better than Catalent
- What is a Stock Market Index and How Do You Use Them?
- JetBlue Airlines May Have Entered A Buy Zone, Check This First
- What is a SEC Filing?
- Investors Are Staying Bullish On Marriot International
- Consumer Staples Stocks, Explained
- Do Caterpillar’s Results Hint at a Looming Infrastructure Bubble?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT – Free Report).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
